CN118924896A - 阿尔茨海默病的治疗及预防方法 - Google Patents

阿尔茨海默病的治疗及预防方法 Download PDF

Info

Publication number
CN118924896A
CN118924896A CN202411217698.2A CN202411217698A CN118924896A CN 118924896 A CN118924896 A CN 118924896A CN 202411217698 A CN202411217698 A CN 202411217698A CN 118924896 A CN118924896 A CN 118924896A
Authority
CN
China
Prior art keywords
months
subject
relative
composition
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411217698.2A
Other languages
English (en)
Chinese (zh)
Inventor
J·鲁特曼
C·J·斯万森
Y·张
S·达达
J·王
L·克拉默
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanitary Material R&d Management Co ltd
Original Assignee
Sanitary Material R&d Management Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanitary Material R&d Management Co ltd filed Critical Sanitary Material R&d Management Co ltd
Publication of CN118924896A publication Critical patent/CN118924896A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
CN202411217698.2A 2018-07-24 2019-07-23 阿尔茨海默病的治疗及预防方法 Pending CN118924896A (zh)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201862702659P 2018-07-24 2018-07-24
US62/702,659 2018-07-24
US201862749614P 2018-10-23 2018-10-23
US62/749,614 2018-10-23
US201962824162P 2019-03-26 2019-03-26
US62/824,162 2019-03-26
US201962846902P 2019-05-13 2019-05-13
US62/846,902 2019-05-13
US201962874684P 2019-07-16 2019-07-16
US62/874,684 2019-07-16
CN201980062781.8A CN112805031A (zh) 2018-07-24 2019-07-23 阿尔茨海默病的治疗及预防方法
PCT/US2019/043067 WO2020023530A2 (en) 2018-07-24 2019-07-23 Methods of treatment and prevention of alzheimer's disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980062781.8A Division CN112805031A (zh) 2018-07-24 2019-07-23 阿尔茨海默病的治疗及预防方法

Publications (1)

Publication Number Publication Date
CN118924896A true CN118924896A (zh) 2024-11-12

Family

ID=67551415

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411217698.2A Pending CN118924896A (zh) 2018-07-24 2019-07-23 阿尔茨海默病的治疗及预防方法
CN201980062781.8A Pending CN112805031A (zh) 2018-07-24 2019-07-23 阿尔茨海默病的治疗及预防方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980062781.8A Pending CN112805031A (zh) 2018-07-24 2019-07-23 阿尔茨海默病的治疗及预防方法

Country Status (13)

Country Link
US (1) US20210324056A1 (https=)
EP (1) EP3826674A2 (https=)
JP (2) JP7541505B2 (https=)
KR (1) KR20210039402A (https=)
CN (2) CN118924896A (https=)
AU (1) AU2019309938B2 (https=)
BR (1) BR112021001272A2 (https=)
CA (1) CA3107370A1 (https=)
IL (3) IL310132B2 (https=)
MX (1) MX2021000778A (https=)
PH (1) PH12021500006A1 (https=)
TW (1) TW202019471A (https=)
WO (1) WO2020023530A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
KR20220156534A (ko) * 2020-03-20 2022-11-25 에자이 알앤드디 매니지먼트 가부시키가이샤 고농도 항-Aβ 프로토피브릴 항체 제형물 및 이의 사용 방법
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
MX2023000949A (es) 2020-07-23 2023-02-22 Othair Prothena Ltd Anticuerpos anti-beta-amiloide (abeta).
WO2022035758A1 (en) * 2020-08-12 2022-02-17 The Cleveland Clinic Foundation Bace1 inhibitor treatment for suppressing cytokine storm
TW202300517A (zh) * 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
KR20240115910A (ko) * 2021-12-17 2024-07-26 에자이 알앤드디 매니지먼트 가부시키가이샤 항-아밀로이드 베타 원섬유 항체 및 항-타우 항체의 사용 방법
WO2023111618A1 (en) * 2021-12-17 2023-06-22 Eisai R&D Management Co., Ltd. Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
MX2024009492A (es) * 2022-02-02 2024-08-09 Eisai R&D Man Co Ltd Metodos de tratamiento mediante el uso del nivel de proteina tau fosforilada 181 (p-tau181).

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1309341A2 (en) 2000-07-07 2003-05-14 Lars Lannfelt Prevention and treatment of alzheimer's disease
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
AU2016208353B2 (en) * 2007-10-17 2017-07-20 Janssen Alzheimer Immunotherapy Immunotherapy regimes dependent on ApoE status
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
RU2476431C2 (ru) 2008-01-18 2013-02-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Конденсированное производное аминодигидротиазина
PT2448968T (pt) 2009-06-29 2021-04-30 Bioarctic Ab ANTICORPOS SELETIVOS PARA PROTOFIBRILAS/OLIGÓMEROS DE ß- AMILOIDE TRUNCADA EM N-TERMINAL
JP2013521233A (ja) * 2010-02-25 2013-06-10 ヤンセン アルツハイマー イミュノセラピー Ａβを標的とする免疫療法のＰＥＴモニタリング
CA2789963C (en) 2010-02-26 2019-09-03 Bioarctic Neuroscience Ab Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
US8426584B2 (en) 2011-01-21 2013-04-23 Eisai R&D Management Co., Ltd. Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives
EP3166970B1 (en) * 2014-07-10 2021-03-10 BioArctic AB Improved a-beta protofibril binding antibodies
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
BR112018014762A2 (pt) * 2016-01-20 2018-12-26 Genentech Inc método de tratamento da doença de alzheimer (da) precoce
ES2939373T3 (es) * 2016-05-13 2023-04-21 Pasteur Institut Inhibición de los receptores de acetilcolina nicotínicos beta-2 para tratar la patología de la enfermedad de Alzheimer
TWI798751B (zh) * 2016-07-01 2023-04-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
CN117244056A (zh) * 2016-10-27 2023-12-19 卫材研究发展管理有限公司 用于治疗阿尔茨海默病的含有抗Aβ初原纤维抗体和β-分泌酶BACE1抑制剂的组合物

Also Published As

Publication number Publication date
AU2019309938A1 (en) 2021-03-11
IL280315B2 (en) 2024-06-01
WO2020023530A3 (en) 2020-03-12
EP3826674A2 (en) 2021-06-02
IL280315A (en) 2021-03-25
WO2020023530A2 (en) 2020-01-30
AU2019309938B2 (en) 2026-04-02
PH12021500006A1 (en) 2021-09-13
CA3107370A1 (en) 2020-01-30
JP7541505B2 (ja) 2024-08-28
KR20210039402A (ko) 2021-04-09
BR112021001272A2 (pt) 2021-04-27
CN112805031A (zh) 2021-05-14
TW202019471A (zh) 2020-06-01
IL280315B1 (en) 2024-02-01
IL310132B1 (en) 2025-11-01
IL310132B2 (en) 2026-03-01
IL323583A (en) 2025-11-01
US20210324056A1 (en) 2021-10-21
IL310132A (en) 2024-03-01
JP2024112859A (ja) 2024-08-21
MX2021000778A (es) 2021-03-31
JP2021532126A (ja) 2021-11-25

Similar Documents

Publication Publication Date Title
CN118924896A (zh) 阿尔茨海默病的治疗及预防方法
CA2163966A1 (en) Alkaline and acid phosphatase inhibitors in treatment of neurological disorders
JP2018111723A (ja) アルツハイマー病を処置するためのｉｌ−１アンタゴニストを使用する方法
JP2024525559A (ja) アルツハイマー病治療用バイオマーカー
KR20240142535A (ko) P-tau181 수준을 사용한 치료 방법
EP4626918A1 (en) Methods of treatment using a tau pet level
RU2832167C2 (ru) Способы лечения и предупреждения болезни альцгеймера
CN117940773A (zh) 用于阿尔茨海默病治疗的生物标记物
HK40118843A (zh) 阿尔茨海默病的治疗及预防方法
CN117999094A (zh) 抗Aβ初原纤维抗体的皮下配制品及其使用方法
BR122025003268A2 (pt) Métodos de tratamento e prevenção de doença de alzheimer
TW202518027A (zh) 抗微生物肽
CN118786141A (zh) 使用p-tau181水平的治疗方法
KR20260022396A (ko) 항-Aβ 프로토피브릴 항체를 사용한 치료 방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40118843

Country of ref document: HK